Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/15/2002US6464998 Composition for the in vivo production of therapeutic products
10/15/2002CA2253795C Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
10/15/2002CA2191837C Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
10/15/2002CA2091766C Enhancement of glutathione levels with glutamine
10/15/2002CA2071912C Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
10/15/2002CA2066943C Heterocyclically substituted phenylacetic acid derivatives, processes for their preparation and their use in medicaments
10/15/2002CA2038985C Haloethyl-substituted steroidal enzyme inhibitors
10/10/2002WO2002079478A2 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
10/10/2002WO2002079404A2 Cytoskeleton-associated proteins
10/10/2002WO2002079236A1 Alpha conotoxin peptides with analgesic properties
10/10/2002WO2002079220A2 Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
10/10/2002WO2002079200A1 3-heterocyclylpropanohydroxamic acid as procollagen c-proteinase inhibitors
10/10/2002WO2002079199A1 Thiophene derivatives and use thereof
10/10/2002WO2002079198A1 Pyridazinone aldose reductase inhibitors
10/10/2002WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002WO2002079194A1 Ccr5 antagonists useful for treating aids
10/10/2002WO2002079193A1 Inhibitors of cyclin dependent kinases as anti-cancer agent
10/10/2002WO2002079192A1 Novel tyrosine kinase inhibitors
10/10/2002WO2002079188A1 Pyrrolidine sulfonamides
10/10/2002WO2002079175A1 3-heterocyclylpropanohydroxamic acid pcp inhibitors
10/10/2002WO2002079170A2 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
10/10/2002WO2002079168A1 Imidazolyl derivatives useful as histamine h3 receptor ligands
10/10/2002WO2002079167A1 Geldanamycin derivative and method of treating cancer using same
10/10/2002WO2002079165A1 Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
10/10/2002WO2002079162A1 Carboxylic acids
10/10/2002WO2002079155A1 Pyrrolidine sulfonamides
10/10/2002WO2002079154A1 Substituted carbazoles as inhibitors of spla2
10/10/2002WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002WO2002079143A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/10/2002WO2002078747A2 Pregabalin lactose conjugates
10/10/2002WO2002078745A2 Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
10/10/2002WO2002078731A1 Module of pd-1 interactions with its ligands
10/10/2002WO2002078716A2 Methylated promoters for intraductal treatment of breast cancer
10/10/2002WO2002078707A1 Pyrrolidine sulfonamides
10/10/2002WO2002078705A1 Hsp inductor
10/10/2002WO2002078704A1 Use of cyclopamine in the treatment of psoriasis
10/10/2002WO2002078703A1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
10/10/2002WO2002078699A1 Compounds and methods
10/10/2002WO2002078696A1 Compounds and methods
10/10/2002WO2002078691A1 Duloxetine for treatment of hot flashes
10/10/2002WO2002078685A1 Drugs for vascular lesion
10/10/2002WO2002078683A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002WO2002078682A2 Estrogen replacement therapy
10/10/2002WO2002078680A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002WO2002078671A1 Medical aerosol formulations
10/10/2002WO2002078648A2 Topical composition comprising an antifungal
10/10/2002WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002WO2002078640A2 Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
10/10/2002WO2002078639A2 A method of treating proliferative diseases using eg5 inhibitors
10/10/2002WO2002078629A2 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
10/10/2002WO2002078627A2 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
10/10/2002WO2002078620A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
10/10/2002WO2002078600A2 γεRACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA
10/10/2002WO2002078598A2 Peptides and antibodies to muc 1 proteins
10/10/2002WO2002078468A1 Food or beverage for vascular disorder or disease
10/10/2002WO2002062795A9 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
10/10/2002WO2002060386A3 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
10/10/2002WO2002058636A3 Novel cannabimimetic ligands
10/10/2002WO2002057287A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
10/10/2002WO2002046373A8 Method of collecting placental stem cells
10/10/2002WO2002046178A3 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
10/10/2002WO2002034895A3 Novel aggrecanase molecules
10/10/2002WO2002026820A3 Immunomodulatory protein derived from the yaba monkey tumor virus
10/10/2002WO2002010766A3 Assay method, peptides and reagent kits for testing mrp-specific inhibitors
10/10/2002WO2002004612A3 Drug metabolizing enzymes
10/10/2002WO2001095929A3 Interferon for treatment of multiple sclerosis
10/10/2002WO2001095895A3 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
10/10/2002WO2001093845A3 Carboxyalkylether-acat inhibitor combinations
10/10/2002WO2001077174A3 Human transporters and ion channels
10/10/2002WO2001074382A9 Method of treatment using ligand-immunogen conjugates
10/10/2002WO2001072728A9 Novel piperazine derivatives
10/10/2002WO2001072685A9 Polyamine analogues as cytotoxic agents
10/10/2002WO2001049678A9 Substituted phenyl-piperazine derivatives, their preparation and use
10/10/2002US20020147359 Neurokinin antagonist; antiinflammatory agents, antiallergens
10/10/2002US20020147343 Cell antiproliferative agents; anticancer agents
10/10/2002US20020147341 Kinase inhibitor; benign prostatic hyperplasia
10/10/2002US20020147339 5-cyano-2-aminopyrimidine derivatives
10/10/2002US20020147336 Glucocorticoid receptor modulators
10/10/2002US20020147332 Novel nucleoside and oligonucleotide analogues
10/10/2002US20020147325 Antibodies to receptor protein kinases
10/10/2002US20020147316 Medical diagnosis, therapy
10/10/2002US20020147310 Nucleotide sequences coding polypeptides for use in the treatment of inflammatory and autoimmune diseases
10/10/2002US20020147306 Peptides that modulate the interaction of B class ephrins and PDZ domains
10/10/2002US20020147305 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/10/2002US20020147239 Esmolol formulation
10/10/2002US20020147237 Preservation of bodily protein
10/10/2002US20020147234 Nitrate esters and methods of making same
10/10/2002US20020147233 Epoxyvibsanin B
10/10/2002US20020147231 Allosteric adenosine receptor modulators
10/10/2002US20020147224 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
10/10/2002US20020147222 Brain disorders; Alzheimer's disease
10/10/2002US20020147220 Norcisapride; sleep disorders, eating disorders, irratible bowel disorders
10/10/2002US20020147218 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
10/10/2002US20020147213 Side effect reduction; synergistic mixture
10/10/2002US20020147206 Synergistic mixture of neurotransmitter and antidepressant
10/10/2002US20020147205 Heterocyclic compounds
10/10/2002US20020147203 Tyrosine kinase inhibitors
10/10/2002US20020147201 Glycyrrhizin complex
10/10/2002US20020147198 Substituted arylamine derivatives and methods of use
1 ... 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 ... 1564